Scientists test re-engineered immune cells to fight advanced cancers
NCT ID NCT06375187
Summary
This early-stage study is testing a new type of personalized cell therapy called GC203 TIL in adults with advanced solid tumors that have stopped responding to standard treatments. Doctors take a patient's own immune cells from a tumor, modify them in a lab to potentially fight cancer better, and then infuse them back into the patient. The main goals are to find a safe dose and see if this approach can help control cancers like ovarian, breast, lung, and gastrointestinal tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.